BCAL Diagnostics Limited
Research BCAL Diagnostics Limited (BDX.AX) on Bullrun: market cap AUD 29.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDX.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyAUD
- Market capAUD 29.13M
- Financial periodFY2025
- RevenueAUD 21.64K
- Net income-AUD 7.24M
- Free cash flow-AUD 6.92M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 29.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 21.64K | -AUD 7.24M | -AUD 6.92M | 100.0% | -0.02 | AUD 4.52M | AUD 2.38M | AUD 6.22M |
| FY2024 | n/a | -AUD 6.40M | -AUD 5.67M | n/a | -0.03 | AUD 6.47M | AUD 1.52M | AUD 8.59M |
| FY2023 | n/a | -AUD 5.06M | -AUD 6.05M | n/a | -0.02 | AUD 3.17M | AUD 1.06M | AUD 5.21M |
| FY2022 | n/a | -AUD 3.39M | -AUD 7.25M | n/a | -0.02 | AUD 5.57M | n/a | AUD 9.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 29.13M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BCAL Diagnostics Limited's market cap?
BCAL Diagnostics Limited's market capitalization is AUD 29.13M.
What does BCAL Diagnostics Limited do?
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.